|Company Name||BioScrip, Inc.|
On March 8, 2018, BioScrip announced a delay in the filing of its annual report, because the Company had begun an internal accounting review after BioScrip "identified internal control deficiencies in connection with account reconciliations for certain asset and liability accounts." The Company additionally announced that it "has identified and will report a material weakness related to certain spreadsheets used to calculate periodic adjustments to" certain accounts.
On this news, BioScrip's share price fell $0.47, or 15%, to close at $2.60 on March 8, 2018, thereby injuring investors.
Submit Your Information
If you suffered a loss on your BioScrip, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.